Substituted lactams showing serotonin 5-HT receptor activity

1. A compound of Formula (1):

or a pharmaceutically acceptable salt thereof,

wherein:

Ring Q 1 is Formula (2):

wherein:

Ring Q 3 is a 5- or 6-membered aromatic heterocyclic ring;

wherein the 5- or 6-membered aromatic heterocyclic ring is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, NH 2 , OH, OC 1-6 alkyl, and C 3-10 cycloalkyl;

wherein each C 1-6 alkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and OC 1-6 alkyl;

wherein each NH 2 substituent of Ring Q 3 is optionally and independently substituted with 1 or 2 independently selected C 1-6 alkyl substituents;

wherein each OC 1-6 alkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and

wherein each C 3-10 cycloalkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

W is —CR c R D —;

X is —CH 2 —;

Y is N;

m is 0;

bond (b) is a single bond; and

is the point of attachment to V;

Ring Q 2 is Formula (3a) or Formula (3b):

wherein:

is the point of attachment to Z;

each V is independently —CR A R B —;

Z is C, CR J , or N;

R 1a is hydrogen, halogen, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1b is hydrogen, halogen, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1c is hydrogen, halogen, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1d is hydrogen, halogen, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 2a is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl or OC 1-6 alkyl of R 2a is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH 2 of R 2a is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents;

R 2b is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl or OC 1-6 alkyl of R 2b is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH 2 of R 2b is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents;

R 2C is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl or OC 1-6 alkyl of R 2C is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH 2 of R 2c is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents;

R 2d is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl or OC 1-6 alkyl of R 2d is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH 2 of R 2d is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents;

each R A is independently hydrogen, C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl, wherein each C 1-6 alkyl, OC 1-6 alkyl, and C 3-10 cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

each R B is independently hydrogen, C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl, wherein each C 1-6 alkyl, OC 1-6 alkyl, and C 3-10 cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

R C is hydrogen, C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl, wherein the C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R D is hydrogen, C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl, wherein the C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R J is hydrogen, C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl, wherein the C 1-6 alkyl, OC 1-6 alkyl, or C 3-10 cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

bond (a) is a single or double bond;

n is 1 or 2; and

t is 2;

with the provisos that:

(I) when Ring Q 3 is an optionally substituted 5-membered aromatic heterocyclic ring, then R 2a is hydrogen, R 2b is hydrogen, R 2c is hydrogen, and R 2d is hydrogen; and

(II) when bond (a) is a double bond, then Z is C.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring Q 3 is a 5- or 6-membered aromatic heterocyclic ring;

wherein the 5- or 6-membered aromatic heterocyclic ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, OC 1-6 alkyl, and C 3-10 cycloalkyl;

wherein each C 1-6 alkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

wherein each OC 1-6 alkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and

wherein each C 3-10 cycloalkyl substituent of Ring Q 3 is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is CH.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is N.

5. The compound according to claim 1 , wherein the compound is of Formula (1a):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1a is hydrogen or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1b is hydrogen or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1c is hydrogen or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 1d is hydrogen or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents.

6. The compound according to claim 1 , wherein the compound is of Formula (1b):

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring Q 1 is Formula (4a), Formula (4b), Formula (4c), or Formula (4e):

wherein:

R 3a is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl of R 3a is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

wherein the NH 2 of R 3a is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents; and

wherein the OC 1-6 alkyl of R 3a is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R 3b is hydrogen, halogen, cyano, C 1-6 alkyl, NH 2 , or OC 1-6 alkyl;

wherein the C 1-6 alkyl of R 3b is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

wherein the NH 2 of R 3b is optionally substituted with 1 or 2 independently selected C 1-6 alkyl substituents; and

wherein the OC 1-6 alkyl of R 3b is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

is the point of attachment to V.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring Q 1 is Formula (5a), Formula (5b), Formula (5c), or Formula (5d):

wherein:

R 4a is C 1-6 alkyl or OC 1-6 alkyl;

R 4b is hydrogen or C 1-6 alkyl; and

is the point of attachment to V.

9. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring Q 2 is Formula (3a):

wherein:

is the point of attachment to Z.

10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring Q 2 is Formula (3b):

wherein:

is the point of attachment to Z.

11. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1a is hydrogen;

R 1b is hydrogen;

R 1c is hydrogen; and

R 1d is hydrogen.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2a is hydrogen;

R 2b is hydrogen;

R 2C is hydrogen; and

R 2d is hydrogen.

13. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R A is independently hydrogen; and

each R B is independently hydrogen.

14. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein bond (a) is a single bond.

15. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 2.

16. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

17. A drug comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, as an active ingredient.

18. A medicament comprising a pharmaceutically acceptable excipient, at least one drug, and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, as an active ingredient;

wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an antiepileptic drug, an antimigraine drug, an antiparkinsonian drug, an antischizophrenic agent, an anxiolytic drug, a dopamine receptor agonist, a dopamine supplement, a hormone preparation, a drug for treating a mood disorder, and a sleep-inducing drug.

19. A method for treating a central nervous system disease or disorder or a mental disease or disorder in a patient, wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

20. The method according to claim 19 , wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of a behavioral disorder due to psychoactive substance use, a behavioral disorder with onset usually occurring in childhood, a behavioral disorder with onset usually occurring in adolescence, a degenerative disease of the central nervous system, a delusional disorder, an emotional disorder with onset usually occurring in childhood, an emotional disorder with onset usually occurring in adolescence, an extrapyramidal movement disorder, a mental disorder due to psychoactive substance use, a mood affective disorder, a neurotic disorder, an organic mental disorder, a pervasive developmental disorder, schizophrenia, a schizotypal disorder, sexual dysfunction not caused by an organic disorder or organic disease, a sleep disorder, a somatoform disorder, and a stress-related disorder.

21. The method according to claim 20 , wherein the sleep disorder is a nonorganic sleep disorder.

22. The method according to claim 19 , wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, a bipolar disorder with a psychotic feature, a depressive disorder with a psychotic feature, irritation associated with Alzheimer's disease, a negative symptom of schizophrenia, a positive symptom of schizophrenia, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, a psychopathic symptom associated with Parkinson's disease, and schizophrenia.

23. The method according to claim 22 , wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

24. The method according to claim 22 , wherein the psychopathic symptom associated with Parkinson's disease is a psychopathic symptom associated with Parkinson's disease with dementia.

25. The method according to claim 19 , wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, irritation associated with Alzheimer's disease, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, and schizophrenia.

26. The method according to claim 25 , wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

27. A method for treating a central nervous system disease or disorder or a mental disease or disorder in a patient, wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of at least one drug and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, as an active ingredient;

wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an antiepileptic drug, an antimigraine drug, an antiparkinsonian drug, an antischizophrenic agent, an anxiolytic drug, a dopamine receptor agonist, a dopamine supplement, a hormone preparation, a drug for treating a mood disorder, and a sleep-inducing drug.

28. The method according to claim 27 , wherein first at least one drug is administered to the patient, and second the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, is administered to the patient.

29. The method according to claim 27 , wherein first the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, is administered to the patient, and second at least one drug is administered to the patient.

30. The method according to claim 27 , wherein at least one drug and the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, are administered to the patient concurrently.

31. A method for treating a central nervous system disease or disorder or a mental disease or disorder in a patient, wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of a medicament comprising a pharmaceutically acceptable excipient, at least one drug, and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, as an active ingredient;

wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an antiepileptic drug, an antimigraine drug, an antiparkinsonian drug, an antischizophrenic agent, an anxiolytic drug, a dopamine receptor agonist, a dopamine supplement, a hormone preparation, a drug for treating a mood disorder, and a sleep-inducing drug.